Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

asciminib 15Cyclophosphamide 12fludarabine phosphate 10Mycophenolic Acid 9fludarabine 8nilotinib 7Whole-Body Irradiation 7Imatinib Mesylate 6Dasatinib 6Tacrolimus 5Sirolimus 5Cyclosporine 5venetoclax 4bosutinib 4Melphalan 4Granulocyte Colony-Stimulating Factor 4ponatinib 3Thiotepa 3Stem Cell Transplantation 3Peripheral Blood Stem Cell Transplantation 3Cyclosporins 3Busulfan 3thymoglobulin 2ruxolitinib 2Specimen Handling 2Mesna 2Magnetic Resonance Spectroscopy 2Filgrastim 2Blood Component Removal 2treosulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × BID protein, human × 90 days × Clear all
NCT04948333 2026-03-18

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Novartis

Phase 3 Completed
199 enrolled 13 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡